Moti Ramgopal

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Pedro Cahn, Anton Pozniak, Horacio Mingrone et al. · The Lancet · 2013 · 507 citations · Full text

Treatment And Prevention, Week 48, Antiviral Drug Development +7

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1

David Wyles, Peter Ruane, Mark Sulkowski et al. · New England Journal of Medicine · 2015 · 418 citations · Full text

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 371 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Week 48 +14

Interleukin-7 promotes HIV persistence during antiretroviral therapy

Claire Vandergeeten, Rémi Fromentin, Sandrina DaFonseca et al. · Blood · 2013 · 235 citations · Full text

Cross-Clade Ultrasensitive PCR-Based Assays To Measure HIV Persistence in Large-Cohort Studies

Claire Vandergeeten, Rémi Fromentin, Esther Merlini et al. · Journal of Virology · 2014 · 227 citations · Full text